<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03612037</url>
  </required_header>
  <id_info>
    <org_study_id>MODCR00002022</org_study_id>
    <nct_id>NCT03612037</nct_id>
  </id_info>
  <brief_title>Impact of Alpha-Lipoic Acid Ingestion on Glucose Tolerance in Subjects With Pre-Diabetes</brief_title>
  <official_title>Impact of Alpha-Lipoic Acid Ingestion on Glucose Tolerance in Subjects With Pre-Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity, with a prevalence of over 35% in American adults, is considered the most critical&#xD;
      threat to the health and well-being of Americans. Obesity-associated metabolic abnormalities,&#xD;
      including hyperglycemia, insulin resistance, and dyslipidemia, contribute substantially to&#xD;
      elevated risk of cardiovascular disease (CVD) and diabetes. Although significant and&#xD;
      sustained lifestyle modifications in diet and exercise are effective in reducing weight and&#xD;
      improving obesity-related metabolic disturbances, long-term compliance to drastic changes in&#xD;
      diet and daily activity patterns is often difficult to attain given the hectic lifestyle of&#xD;
      modern societies. Health-promoting nutraceuticals - naturally occurring bioactive compounds&#xD;
      capable of eliciting targeted molecular responses at the cellular level - may be an effective&#xD;
      and convenient strategy to assist in weight reduction and reduce disease risk factors in&#xD;
      obese individuals. Furthermore, nutraceutical compounds could prove to be a powerful adjunct&#xD;
      to lifestyle and pharmacological weight reduction therapies, as they are relatively safe,&#xD;
      cost effective, and possess the ability to modulate specific, and sometimes multiple,&#xD;
      molecular targets. As a dietary supplement, alpha-lipoic acid appears to have broad molecular&#xD;
      specificity with an impressive array of metabolic health benefits that include weight loss,&#xD;
      reduction in blood lipids, and improved glycemic control. As the effects of alpha-lipoic acid&#xD;
      supplementation for dyslipidemia, hyperglycemia, and body composition through appetite&#xD;
      suppression and increased energy expenditure have been repeatedly confirmed in multiple&#xD;
      animal models, it is surprising that there has been limited effort to translate these&#xD;
      responses to human subjects. Given the strong pre-clinical data supporting the health&#xD;
      benefits of alpha-lipoic acid, there is a clear need to conduct controlled interventions to&#xD;
      address the current clinical knowledge gap and assess if the anti-diabetic effect of Î±-lipoic&#xD;
      acid can be translated to humans.&#xD;
&#xD;
      The primary objective of this application is to determine the efficacy of alpha-lipoic acid&#xD;
      supplementation on glycemic control and body composition in obese pre-diabetic adults. The&#xD;
      investigators hypothesize that alpha-lipoic acid supplementation will improve biomarkers of&#xD;
      diabetes and cardiovascular risk and promote changes in body composition in obese adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>1 month</time_frame>
    <description>blood glucose and insulin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>1 month</time_frame>
    <description>Blood cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>1 month</time_frame>
    <description>Triglycerides</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Control Phase</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>cellulose (600 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alpha lipoic acid (600 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>alpha lipoic acid</intervention_name>
    <description>600 mg/day oral dose of alpha lipoic acid</description>
    <arm_group_label>Experimental Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cellulose</intervention_name>
    <description>600mg/day oral dose of placebo cellulose</description>
    <arm_group_label>Control Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  sedentary individuals (exercises &lt; 2 days/week)&#xD;
&#xD;
          -  fasting blood glucose between 100-125 mg/dl (pre-diabetes)&#xD;
&#xD;
          -  BMI of 25-40.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  physically active lifestyle (exercise &gt; two days/week)&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  history of cigarette smoking&#xD;
&#xD;
          -  medication and/or dietary supplement to control blood glucose, lipids, or blood&#xD;
             pressure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Todd Rideout</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>pre-diabetes</keyword>
  <keyword>glucose</keyword>
  <keyword>insulin</keyword>
  <keyword>blood lipids</keyword>
  <keyword>alpha lipoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

